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LIM kinase 1 (LIMK1)1 belongs to a novel dual specificity
(serine/threonine and tyrosine) kinase family that contain two
amino-terminal LIM domains (1). LIMK1 gene is expressed
predominantly in brain and in developing neural tissues (2),
and its deletion (microdeletion of chromosome 7q11.23) is typical for Williams syndrome (3). Cofilin, one of the actin-binding
proteins, considered to be a potent regulator of the actin dynamics (4) by means of its activity in F-actin depolymerization,
is the only known substrate of LIMK1. The function of cofilin is
inhibited by phosphorylation at the Ser-3 residue (5) by
LIMK1, which leads to accumulation of F-actin. The catalytic
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activity of LIMK1 is regulated by distinct members of the Rho
subfamily of small GTPases (Rho, Rac, and Cdc42), which
controls actin filament dynamics and focal adhesions assembly
in response to extra- and intracellular stimuli. Rho, Rac, and
Cdc42 induce formation of stress fibers, assembly of lamellipodia and membrane ruffles, and regulation of filopodial protrusions, respectively (6). LIMK1 has been shown to mediate specifically Rac-induced actin cytoskeleton reorganization and
focal adhesion complexes (5, 7, 8). Rac-induced activation of
LIMK1 is mediated by PAK1, which phosphorylates LIMK1 on
its Thr508 residue (9). Other studies also proposed that Rhoand Cdc42- induced cytoskeletal changes are mediated through
phosphorylation of LIMK1 by Rho-dependent protein kinase
ROCK (10) and Cdc42-regulated protein kinase PAK4 (11) and
MRCK␣ (12).
The non-catalytic domain of LIMK1 contains two tandem
repeats of a LIM motif, a putative zinc binding motif, and a
PDZ domain, which contains two tandem nuclear exit signal
sequences (7). LIMK1 also contains a nuclear localization signal-like basic cluster sequence. The non-catalytic domain of
LIMK1 has been shown to have effects on cytoskeleton reorganization independent of its kinase activity. Specific regions of
the non-catalytic domain (LIM or PDZ) inhibit neurite outgrowth in differentiating PC12 cells in response to Ras, neuronal growth factor (NGF) or a ROCK inhibitor without altering
endogenous LIMK1 activity (13, 14). These observations suggest that the non-catalytic domain of LIMK1 is involved in
regulating cellular processes though protein-protein interaction. LIMK1 also physically interacts through its LIM domain
with the cytoplasmic tail of neuregulins, a family of transmembrane proteins that functions as receptor tyrosine kinase ligands. These proteins are known to be involved in the regulation of synapse formation and maintenance, cell proliferation,
apoptosis, differentiation, and neuronal migration (15). Deletion experiments have shown that the lack of LIM and PDZ
domains enhances the effect of LIMK1 on actin cytoskeleton
(16). In addition, expression of a kinase-inactive form of the
protein blocked the effect of the native LIMK1 (5). These findings suggest an inhibitory role of the non-catalytic domain in
the regulation of the kinase activity of LIMK1.
Reorganization of cytoskeleton is an essential feature of motility, detachment, and invasion of cancer cells. Individual
members of the Rho family, such as Rac and Cdc42, induce
distinct actin remodeling events, work together at the leading
edge of the cell, and coordinate lamellipodial and filopodial
extensions, whereas Rho activates accumulation of stress fibers
through activation of ROCK (17). Formation and stabilization
of actin filaments are the key events downstream of Rac and
Cdc42, which provide the protrusive force for cellular extensions at the leading edge of the migratory cells (18). Seemingly,
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Mammalian LIM kinase 1 (LIMK1) is involved in reorganization of actin cytoskeleton through inactivating
phosphorylation of the ADF family protein cofilin,
which depolymerizes actin filaments. Maintenance of
the actin dynamics in an ordered fashion is essential for
stabilization of cell shape or promotion of cell motility
depending on the cell type. These are the two key phenomena that may become altered during acquisition of
the metastatic phenotype by cancer cells. Here we show
that LIMK1 is overexpressed in prostate tumors and in
prostate cancer cell lines, that the concentration of
phosphorylated cofilin is higher in metastatic prostate
cancer cells, and that a partial reduction of LIMK1 altered cell proliferation by arresting cells at G2/M,
changed cell shape, and abolished the invasiveness of
metastatic prostate cancer cells. We also show that the
ectopic expression of LIMK1 promotes acquisition of
invasive phenotype by the benign prostate epithelial
cells. Our data provide evidence of a novel role of LIMK1
in regulating cell division and invasive property of prostate cancer cells and indicate that the effect is not mediated by phosphorylation of cofilin. Our study correlates with the recent observations showing a metastasisassociated chromosomal gain on 7q11.2 in prostate
cancer, suggesting a possible gain in LIMK1 DNA
(7q11.23).

LIM Kinase 1 and Prostate Cancer

EXPERIMENTAL PROCEDURES

Cell Culture, Transfection, and Isolation of Stable Cell Line—PC3,
DU145, LNCaP (ATCC), PrEC (Clonetics), BPH-1 (a gift from P.
Narayan, Celebration, FL), p69, M21, and M12 (gift from J. Ware,
Richmond, VA) were maintained in RPMI (DU145, LNCaP, p69, M21,
and M12), Ham-12 (PC3), DMEM (BPH-1) and in specified medium
(PrEC) and grown to log phase before being used as described (27). PC3
cells were transfected using LipofectAMINE (Invitrogen) with the open
reading frame of the LacZ gene or the antisense cDNA of the coding
sequence of LIMK1 (1.94 kilobases), both cloned into an ecdysoneinducible mammalian expression vector (pIND, Invitrogen). BPH-1
cells (benign prostatic hyperplasia) were transfected with the open
reading frames of LIMK1 or LacZ cloned in pIND. Cells were cotransfected with the vector pVRxR that encodes the subunit of a heterodimer of the ecdysone and the retinoid X receptor to establish stable
cell lines (PC3ASL and PC3LacZ) capable of expressing antisense
LIMK1 RNA or LacZ when induced with an ecdysone analogue, ponasterone A. Double stable clones were selected using 500 g/ml Geneticin
(Invitrogen) and 50 g/ml Zeocin (Invitrogen). When mentioned, stably
transfected cells were continuously induced during the times indicated
by adding 5 M ponasterone A (Invitrogen) every 22 h.
Immunoblotting, Immunohistochemistry, and Immunofluorescence—
Total cell lysates were resolved in SDS-PAGE (10 –14%) and subjected
to immunoblotting using anti-LIMK1 (Transduction Laboratories), anti-cofilin (Cytoskeleton), or anti-phospho-cofilin antibodies (Cell Signaling). Anti-glyceraldehyde-3-phosphate dehydrogenase antibody (Biogenesis) was simultaneously used as an internal control. Goat antimouse or anti-rabbit antibody was used as the secondary antibody.
Paraffin-embedded tissue sections of normal and malignant human
prostate were subjected to a pepsin-based antigen retrieval protocol
(BioGenex, San Ramon, CA) followed by incubation with anti-LIMK1
antibody. A biotinylated multi-link goat anti-immunoglobulin for
mouse, rabbit, guinea pig, and rat was used as the secondary antibody.
Positive signals were detected by horseradish peroxidase-conjugated
streptavidin and 3,3⬘-diaminobenzidine (DAB) as the chromogen (BioGenex Multi-Link kit). For indirect immunofluorescence, PC3ASL and
PC3LacZ cells were plated on poly-L-lysine-coated glass cover slips and
continuously induced for 72 h. Cells were permeabilized and dually
stained with Alexa Fluor 488-conjugated phalloidin (Molecular Probes)
and anti-LIMK1, anti-paxillin (Transduction Laboratories), or antiMT1-MMP (Cytoskeleton) antibodies. Cy3-conjugated anti-mouse or
anti-rabbit antibody (Molecular Probes) was used as the secondary
antibody. Fluorescent images were captured in a Zeiss LSM 510 laserscanning confocal microscope.
In Vivo Phosphorylation, Expression of Recombinant Protein, and
Immunecomplex Kinase Assay—BPH-1 and PC3 cells were cultured in
the presence of 1.5 mCi of [32P]orthophosphate for 10 h. Equal amounts
of total cell lysates were subjected to immunoprecipitation with anti-

FIG. 1. LIMK1 is differentially expressed in human prostate
cell lines and prostate tissues. a, immunoblot analysis of LIMK1 in
total lysates of human prostate cell lines. b, expression of LIMK1 in
prostate tissues. Upper panel, Normal/benign areas. Lower panel, cancerous glands. Upper and lower left, Hematoxylin/eosin-stained slides.
Magnification, ⫻100. Upper and lower right, areas from normal and
cancerous tissues are shown in higher magnification (⫻200). Arrows
indicate light staining in basal cells in normal/benign areas (upper
panel) and intense staining in cells in cancerous areas (lower panel).
PrEC, prostate epithelial cells. GAPDH, glyceraldehyde-3-phosphate
dehydrogenase.
cofilin antibody and protein A-agarose beads (Sigma) using the procedure as described (28), and the products were resolved in SDS-PAGE
(14%). Labeled cofilin was detected by autoradiography and PhosphorImager analysis (Amersham Biosciences). Recombinant cofilin was
expressed in Escherichia coli as a His-tagged fusion protein by cloning
the open reading frame of human cofilin into the T7 polymerase driven
pET30Ek/LIC (Novagen) expression vector using specific primers (F,
5⬘-GACGACGACAAGATGGCCTCCGGTGTGGCTG-3⬘, and R, 5⬘-GAGGAGAAGCCC GGTTCACAAAGGCTTGCCC-3⬘). The expression construct was used to transform BL21 (DE3) E. coli cells. Transformed cells
were induced with 1 mM isopropyl-1-thio-␤-D-galactopyranoside at
25 °C, and the expressed cofilin was purified through a Nickel affinity
column (HiTrap Chelating HP columns, Amersham Biosciences).
For immune complex kinase assay, LIMK1 was immunoprecipitated
from PC3 cells cultured under regular conditions using anti-LIMK1
antibody and protein G-agarose (Sigma) beads. Protein G-agarose beads
bound to the immune complex were resuspended in kinase assay buffer
(50 mM HEPES, pH 7.5, 150 mM NaCl, 50 M ATP, 5 mM MgCl2, 5 mM
MnCl2, 10 mM NaF, 1 mM Na3VO4, 3 nM [␥-32P]ATP) and incubated at
30 °C for 20 min with 10 g of recombinant cofilin as the substrate (29).
The reaction mix was resolved in SDS-PAGE (14%), and phosphorylated cofilin was detected by autoradiography and PhosphorImager
analysis.
Invasion Assay—Cells were plated in serum-free media (containing
ponasterone A for transfected cells) on control and Matrigel-coated
membrane containing invasion chambers (BD Biosciences). Cells were
incubated at 37 °C for 22 h in a CO2 incubator using 5% fetal bovine
serum in the lower chamber as the chemoattractant. Invading cells
were stained with Diff-QuickTM stain (DADE) and counted. The percentage of cells that invaded through the Matrigel-coated membranes
was calculated by comparison with the cells passed through the membranes in the control chambers.
[3H]Thymidine Incorporation, Cell Synchronization, and Fluorescence-activated Cell Sorter Analysis—Asynchronous PC3LacZ and
PCASL cells were incubated with 1 Ci of [3H]thymidine in the presence or absence of ponasterone A. At different time points after induction, cells were treated with 5% trichloroacetic acid and lysed using 0.5
3
N NaOH. Incorporation of [ H]thymidine to DNA was measured in a
scintillation counter (Beckman LS 5000 TD). For cell cycle analysis,
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these events are critical for the invasive behavior of the cancer
cells, as the inhibition of Rho kinase activity has been shown to
reduce invasive progress of prostate cancer cells in vivo (19).
Rho proteins are activated by growth factor receptors and their
ligands, for example, EGF and NGF and their respective receptors erbB2 and Trk. Cellular-erbB2 and Trk are often overexpressed and activated in various types of cancers including
prostate cancer (20 –22). Furthermore, c-erbB2 was shown to
enhance the invasiveness and metastatic potential of cancer
cells (20). Similarly, NGF and Trk expressions in prostate
cancer cells coincide with transformation to a malignant phenotype capable of invading along the perineural space and
extracapsular metastasis to a distant site (23). As evident from
membrane ruffling and lamellipodia formation, EGF- and
NGF-induced increased invasion of prostate tumor cells is mediated through Rac (24). Therefore, it is likely that Rac-mediated activation of actin reorganization is mediated through
LIMK1. cDNA microarry and differential display reverse-transcription PCR analyses revealed an up-regulation of LIMK1
mRNA (25) and LIMK1 as the elastin-linked gene (26) in prostate adenocarcinoma cells. This study reports that LIMK1 is
overexpressed in prostate adnocarcinomatous tissues and in
malignant prostate cell lines and is essential for the invasive
property and growth of prostate cancer cells, and the effect is
not mediated through inactivating phosphorylation of cofilin.
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PC3LacZ and PC3ASL cells induced every 22 h were synchronized at
the G1/S boundary by a double thymidine block by treating them with
thymidine (2 mM) for 24 h followed by an 8-h release in fresh growth
medium and successive retreatment with thymidine (2 mM) for 16 h.
Cells were then released to enter the cell cycle in fresh growth medium
and harvested at specified times. Cells were fixed in paraformaldehyde
(1%) in phosphate-buffered saline (PBS), washed in PBS, permeabilized
with saponin (0.25%) in PBS, and treated with RNase (1 mg/ml) at room
temperature. Cells were washed in phosphate-buffered saline and
stained with propidium iodide (400 g/ml) at 37 °C for 30 min. Cells
were analyzed in a flow cytometer (FACScalibur BD Biosciences), and
raw data were analyzed using Modfit (BD Biosciences) software.
RESULTS

LIMK1 Is Overexpressed in Cancerous Prostate Cells and
Tissues and Is Catalytically Active—To confirm the differential
expression of LIMK1 in prostate cancer, we monitored the
expression profile of LIMK1 in various prostate cell lines and
prostate tissues. Our results revealed an increased expression
of LIMK1 in highly aggressive metastatic prostate epithelial
cells and in some prostatic adenocarcinomas (Fig. 1). The concentration of LIMK1 in some cancerous prostate cells (M21 and
M12) increased proportionately with increasing tumorigenic
and aggressive properties compared with normal prostate epithelial cells (P69) and BPH-1 cells (Fig. 1a). A ⬃2–3-fold higher
expression of LIMK1 was noted in tumorigenic (LNCaP and
M21) and metastatic (PC3, DU145, and M12) prostate cancer
cells compared with BPH-1 and P69 (non-tumorigenic) cells
(Fig. 1a). Compared with prostate epithelial cells, the expression of LIMK1 was 5–10-fold higher in the metastatic prostate
cancer cells (PC3 and M21) (Fig. 1a). Consistent with these
findings, immunohistochemical analysis indicated a highly
abundant expression of LIMK1 in some cancerous glands in

prostatic epithelium (Fig 1b). The expression of LIMK1 in
prostate tissues was localized to the basal cells in benign
glands (arrows in Fig. 1b, top: middle and right) compared with
a widespread staining in both the cytoplasm and the nucleus in
the epithelial cells in cancerous glands (arrows in Fig. 1b,
bottom: middle, and right). These results suggest a possible
correlation between overexpression of LIMK1 and phenotypic
differences in prostate tissues.
The abundantly expressed LIMK1 in prostate cancer cells
was catalytically competent as immunoprecipitated LIMK1
(Fig. 2, a and b) from PC3 cells was capable of phosphorylating
recombinant cofilin (Fig. 2c), the only known substrate of
LIMK1 (5). To assess whether the increased expression of
LIMK1 was associated with an increased phosphorylation
of endogenous cofilin, the phosphorylation status of the native
cofilin in BPH-1 and PC3 cells was studied using in vivo phosphorylation and immunoblotting techniques. Although no significant difference in the expression of cofilin was noted in
these two cell lines an appreciable increase in the phosphorylated cofilin was noted in PC3 cells (Fig. 2, d and e), which
demonstrates a parallel increase in phosphorylated cofilin in
these cells.
A Partial Inhibition of LIMK1 Expression Did Not Result in
Reduced Phosphorylation of Cofilin—To understand the possible role of overexpressed LIMK1 in acquisition of tumorigenic
and metastatic phenotypes, we used antisense-RNA mediated
functional inactivation of LIMK1; subsequently, we generated
a stable cell line (PC3ASL) capable of expressing antisense
LIMK1 RNA after induction with an ecdysone analogue, ponasterone A. A time course study using PC3ASL and a control
transformed cell line, PC3LacZ, after continuous induction ev-
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FIG. 2. A higher concentration of phosphorylated cofilin is associated with overexpression of LIMK1 in PC3 cells. a and b, LIMK1
concentration in BPH-1 and PC3 cells before (a) and after (b) immunoprecipitation (IP) with anti-LIMK1 antibody. IB, immunoblot. Sup,
supernatant. c, in vitro phosphorylation of recombinant cofilin by LIMK1 immunoprecipitated from PC3 cells. d, in vivo phosphorylation of cofilin
in BPH-1 and PC3 cells. Immunoblot analysis of cell lysates before immunoprecipitation shows the initial concentration of cofilin in both samples
(lower panel). e, immunoblot analysis of phosphorylated cofilin or cofilin in crude cell extracts using anti-phospho-cofilin or anti-cofilin antibodies.
GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
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ery 20 –22 h for 72 h indicated the maximum expression of
LIMK1 antisense transcript at 72 h, which was associated with
a concurrent decrease in the concentration of the sense LIMK1
transcript only in the induced PC3ASL cells (Fig. 3a). No decrease in the LIMK1 transcript was apparent in any of the
PC3LacZ cells induced or not or in uninduced PC3ASL cells
(Fig. 3, a and b). A parallel reduction in the LIMK1 protein
concentration confirmed the decreased synthesis of LIMK1 in
PC3ASL cells (Fig. 3c). Immunoblot analysis using anti-cofilin
or anti-phospho-cofilin antibodies revealed no simultaneous
decrease in the concentration of phosphorylated cofilin in
PC3ASL cells (Fig. 3d). This observation suggests two possibilities, either the residual LIMK1 can be catalytically more efficient and maintain an increased concentration of phosphorylated cofilin or the enhanced phosphorylation of cofilin was not
mediated by LIMK1. Although cofilin is the only known substrate of LIMK1, it can be phosphorylated by other serine/
threonine kinases, such as LIMK2 (8) and TESK1/TESK2 (30).
Reduced Expression of LIMK1 Retarded Cell Proliferation by
Arresting Cells at G2/M Phase—The effect of reduced expression of LIMK1 on cell proliferation and cell cycle progression
was studied next. Because LIMK1 is expressed in a growth
phase-dependent manner, which suggests its possible involvement in regulation of cell growth (31), we monitored the growth
pattern of induced and non-induced PC3ASL and PC3LacZ
cells by [3H]thymidine incorporation assay. Our results indicated that the inhibition of expression of LIMK1 led to a block
in [3H]thymidine incorporation only in PC3ASL cells after 48 h
of continuous induction (Fig. 4a), signifying a growth arrest in
PC3ASL cells. A possible role of active LIMK1 in regulating
mitosis has been suggested also, based on the studies that have
shown that the LIMK1 activity fluctuates with cell cycle pro-

gression and attains a maximum level during mitosis when
LIMK becomes hyperphosphorylated, presumably by mitotic
Cdks (29, 32). We used induced PC3ASL and PC3LacZ cells
synchronized at G1/S boundary by double thymidine block and
monitored cell cycle progression by harvesting cells at different
time points after the release of the block. At 0 h, ⬃75–78% of
PC3ASL and PC3LacZ cells were at G1/S phase. The remaining
23–25% of cells were at G2/M phase, which could be accounted
for by the higher DNA content in a subpopulation of PC3 cells
with inherent chromosomal gain (33). After the release of thymidine block, both cell types exhibited progression through S
phase (⬃60% cells) and G2/M (⬃30% cells) during the next 6 h.
PC3LacZ cells started to cycle through G1 as a gradual increase
in the percent of cells in G1 was noted with a concurrent
decrease in the total percent of cells in S and G2/M phases
between 6 –14 h (Fig. 4, b and c). In contrast, PC3ASL cells
started to accumulate in G2/M phase during this time (⬃50%
cells at 14 h), indicating a G2/M arrest in these cells (Fig. 4, b
and d). No block in the cell cycle progression in PC3LacZ cells
(Fig. 4, b and c) confirms that a threshold concentration of
LIMK1 is necessary for the passage of cells through G2/M
phase. This result is also consistent with the [3H]thymidine
incorporation data, indicating a growth arrest in PC3ASL cells.
Reduced Expression of LIMK1 Abolished the Invasive Behavior of Prostate Cancer Cells—The effect of inhibition of LIMK1
expression on the invasive property of PC3 cells was studied
next using an in vitro invasion assay. Consistent with their
highly metastatic ability, a 3-fold higher percentage of untransfected PC3 cells were invasive and migrated through the Matrigel compared with the non-invasive BPH-1 cells (Fig. 5, a
and b). A partial inhibition of LIMK1 expression in PC3ASL
cells resulted in a 4 –5-fold decrease in the percent of invaded
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FIG. 3. LIMK1 was effectively reduced in PC3ASL cells by expression of antisense LIMK1, but there was no concurrent reduction
in cofilin phosphorylation. a and b, RNA blot analysis of LIMK1 in PC3ASL (a) and PC3LacZ (b) cells induced successively (⫹) or not (⫺). AS,
antisense. c, concentration of LIMK1 in transfected PC3 cells harvested at different time points after successive induction. d, concentration of
phosphorylated cofilin (P-cofilin) or cofilin in transfected PC3 cells after continuous induction. Despite the reduced concentration of LIMK1 no
noticeable difference in phospho-cofilin concentration was detected in PC3ASL cells. WB, Western blot. GAPDH, glyceraldehyde-3-phosphate
dehydrogenase.
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cells compared with that in the wild type PC3 and PC3LacZ
cells (transfection control), which was comparable with the
percent of BPH-1 cells invaded through the membranes. These
data confirm that the functional LIMK1 is essential for the
invasive function of PC3 cells.
To further confirm the role of LIMK1 in promoting invasiveness of prostate epithelial cells, the effect of ectopic expression
of LIMK1 or LacZ (as the control) in non-invasive BPH-1 cells
was studied. Expression of LIMK1 in transfected BPH-1 cells
after induction by ponasterone A showed predominantly cytoplasmic localization of LIMK1 (Fig. 5d) and altered the growth
pattern from a clustered and patchy appearance (BPHLacZ)) to
a more uniform distribution of single cells (BPHL) (Fig. 6, i and
j). More importantly, expression of LIMK1 in ponasterone Atreated BPHL cells significantly increased the percentage of
invasive cells (13-fold) compared with BPH-1 cells expressing
LacZ (Fig. 5, a and c), suggesting acquisition of a new invasive
phenotype by the non-invasive prostate cells. This study provides compelling evidence that LIMK1 is one of the key proteins that promotes invasiveness and suggests that the increased expression of LIMK1 in PC3 cells may render them
metastatic.
Altered Expression of LIMK1 Changes Cell Morphology and
Organization of Actin Cytoskeleton—The dynamic regulation of
actin cytoskeleton and the adhesion apparatus and the extracellular matrix degradation are both required for the invasion
process of tumor cells. Therefore, we monitored possible alterations in these processes following reduced expression of

LIMK1 in PC3 cells. The induced PC3LacZ cells exhibited cell
morphology that is typically observed in PC3 cells, with smooth
edges and the occasional presence of the filopodial spike-like
structures extended from one or both ends of the cell and, in
some cases, a phase dense border, characteristic of ruffling
lamellipodia around an extensive area of the cell periphery
(Fig. 6a, arrows). A majority of induced PC3ASL cells, however,
showed a more flattened and irregular shape, with several dark
patches at the periphery of the cell (arrows in Fig. 6b) that
appear to be possible adhesion points. Fluorescent staining of
actin cytoskeleton showed a prominent actin meshwork, characteristic of lamellipodia formation at the leading edge of the
induced PC3LacZ cells (Fig. 6c, middle and right); this meshwork was also typical of parental PC3 cells (data not shown)
and of motile cells. Immunolocalization of LIMK1 (Fig. 6c)
showed a perinuclear distribution, with distinct targeting to
the ruffles at the leading edge of these cells (arrows in Fig. 6c,
left). In contrast, a high percentage of induced PC3ASL cells
showed a predominant formation of discrete stress fibers and
focal adhesions typically observed in non-motile adherent cells
(34) (Fig. 6d, middle and right). Distribution of LIMK1 in these
cells was also perinuclear, with one or more broad areas of
accumulation (arrows) at the periphery of the cell (Fig. 6d, left).
Any change in the adhesion system in PC3ASL and PC3LacZ
cells was investigated next by monitoring immunolocalization
of paxillin, an adapter protein associated with focal adhesions
of adherent cells (17, 35, 36) (Fig. 6e). Similar to the parental
PC3 cells (data not shown), PC3LacZ cells showed the presence
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FIG. 4. The reduced expression of LIMK1 in PC3 cells is associated with suppression of cell growth and cell cycle arrest in G2/M
phase. a, [3H]thymidine incorporation in PC3ASL and PC3LacZ cells induced successively (I) or not (N). Data represent values relative to the
initial time point (0 h) and as the mean ⫾ S.E of three independent experiments. b– d, flow cytometric analysis of cell cycle transition in
synchronized PC3LacZ (c) and PC3ASL (d) cells successively induced for 72 h. Cells were arrested at the G1/S boundary and released. b, percentage
of cells at different stages of cell cycle. Cell cycle profiles show similar progression of PC3ASL and PC3LacZ cells to the S and G2/M phase up to
6 h after release, but only PC3LacZ cells continue to G1 and S phase, whereas PC3AL cells undergo a G2/M arrest from 10 h onwards.
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of paxillin as broad areas surrounding the nucleus and small
adhesion sites at the cell periphery, which overlapped the actin
meshwork that forms the lamellipodia (arrows in Fig. 6e, left,
middle, and right). In contrast, paxillin was more centrally
localized in PC3ASL cells, with frequent accumulation in broad
areas between the actin meshwork (arrows) representative of
stress fibers (Fig. 6f, left, middle, and right) and the cell
boundary.
Published reports indicated an elevated expression of the
membrane-type matrix metalloproteinase MT1-MMP in invasive prostate cancer cells (38) such as PC3 and DU145 and its
intense staining in selected secretory glands in cancerous prostate tissues (39). Because the localization of MT1-MMP to the
lamellipodia has been correlated with the invasive properties of
cells (40 – 42) we monitored the distribution of this protein in
PC3ASL and PC3LacZ cells. Distribution of MT1-MMP in induced PC3LacZ was localized to the perinuclear and to the
lamellipodia along with actin (arrows in Fig. 6g, left, middle,
and right) but mainly in the perinuclear region in PC3ASL cells

(Fig. 6h) and between actin stress fibers (enlarged box). These
results suggest that a reduction in LIMK1 concentration induced changes in the actin cytoskeleton reorganization, the
adhesion pattern, and localization of MT1-MMP in PC3 cells.
DISCUSSION

In this paper we have shown that the expression of LIMK1,
one of the proteins that modulates actin dynamics, is up-regulated in adenocarcinomatous prostatic epithelium and prostate
cancer cell lines. The degree of expression of LIMK1 showed a
correlation with the aggressiveness of cancer cells. For example, expression of LIMK1 was higher in metastatic PC3 cells
and M12 cells compared with less-aggressive LNCaP and M21
cells. Consistent with this observation, expression of LIMK1
was significantly high in cancerous prostate tissues compared
with histologically normal prostatic epithelium. This finding
may explain the consequence of the chromosomal gain on
7q11.2-q31 that is predominantly found in distant metastasis
of prostate tumors (43, 44). Molecular cytogenetic analysis of
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FIG. 5. Altered expression of LIMK1 is associated with changes in the invasiveness of prostate cells. Reduced expression of LIMK1
is associated with a reversion of the invasion ability of PC3 cells. Transfected cells were successively induced for 48 h before being plated in to the
invasion chambers. Ectopic expression of LIMK1 in BPH-1 cells increased invasion significantly after induction with ponasterone A for 24 h. a, fold
difference in invasion in different cell lines. Data represents mean ⫾ S.E. of quantitative analysis of three independent assays (each from two
different clones of transfected PC3 and BPH-1 cells). b and c, bright field images of cells invaded to the underside of the control and Matrigel
membranes. d, staining of LIMK1 in BPHL and BPHLacZ cells showing predominantly cytoplasmic distribution of LIMK1 in BPHL cells. Nuclei
were stained with 4,6-diamidino-2-phenylindole (⫻200).
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prostatic adenocarcinomas indicated a gradual increase for the
number of patients with gain of chromosome 7pq with increasing tumor volume (45). Importantly, these chromosomal alterations are also found in primary tumors that showed progression after radical prostatectomy (46), suggesting a possible
correlation of LIMK1 expression as a biomarker for prostate
cancer progression.
To understand the implication of up-regulated LIMK1 in
prostate cancer, we used BPH-1 and PC3 cells as models for
benign and cancerous prostate cells. PC3 cells are widely used
for studies on invasive behavior of prostate cancer, which also
exhibited increased expression of LIMK1 compared with
BPH-1. Because the function of LIMK1 is mediated through
phosphorylation of cofilin in reorganization of actin cytoskeleton, we studied the status of the kinase activity of immunoprecipitated LIMK1 from PC3 cells, which confirmed that the
endogenous LIMK1 was catalytically active. Interestingly, a
parallel increase in the concentration of endogenous phosphocofilin was also noted in PC3 cells. However, no significant
decrease in the concentration of phospho-cofilin was seen after
enforced reduction of the expression of LIMK1. Presumably, in
PC3 cells, phosphorylation of cofilin is not solely mediated by
LIMK1. A number of studies show that protein kinases differ-

ent from LIMK1 phosphorylate cofilin at Ser-3 as well as at
multiple other sites (8, 28, 47). Although unlikely, it is also
possible that the residual LIMK1 in PC3ASL cells is highly
efficient catalytically and can maintain a higher concentration
of phospho-cofilin.
Our study on antisense-RNA-mediated reduced expression of
LIMK1 provides evidence on the involvement of LIMK1 in
regulation of growth of prostate cancer cells, specifically at the
G2/M phase of the cell cycle. Recent studies show that LIMK1
undergoes mitosis-specific activation by hyperphosphorylation,
which is associated with a concomitant increase in phosphorylation of cofilin (29, 32). LIMK1 becomes activated in prometaphase and metaphase and comes back to the basal level as
cells enter telophase (32), which suggests that a controlled
activity of cofilin by phosphorylation and dephosphorylation is
necessary for mitosis. Our study indicates a direct role of
LIMK1 in G2/M phase, as a partial reduction of LIMK1 expression induced a G2/M arrest in PC3ASL cells. However, it is
uncertain whether the effect of the reduced concentration of
LIMK1 was mediated through the increased activity of cofilin
due to nonphosphorylation since no alteration in phospho-cofilin concentration was noted in these cells. It is possible that
either a subpopulation of dephosphorylated cofilin was main-
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FIG. 6. Reduced expression of LIMK1 is associated with changes in cell morphology, cytoskeleton organization, and the invasive
ability of PC3 cells. a and b, phase-contrast images of PC3LacZ (a) and PC3ASL (b) cells after successive induction for 72 h. c– h, dual staining
of continuously induced PC3LacZ (c, e, and g) and PC3ASL (d, f, and h) cells with Alexa 488-conjugated phalloidin and anti-LIMK1 (c and d),
anti-paxillin (e and f), or MT1-MMP (g and h) antibodies. Arrows indicate localization of LIMK1 in lamellipodia along with actin (c), accumulation
of LIMK1 between actin stress fibers and cell boundary (d), localization of paxillin to the small adhesion points at the lamellipodia along with actin
(e), redistribution of paxillin and accumulation in large areas between actin stress fibers and cell periphery (f), and localization of MT1-MMP (also
in the enlarged section) and actin to the lamellipodia (g). Scale bar, 10 m. i and j, phase contrast images of BPHLacZ (i) and BPHL (j) showing
the difference in growth pattern.
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tained in the nucleus that could not be phosphorylated in
PC3ASL cells upon reduced expression of LIMK1 or the role of
LIMK1 is mediated through its interaction with other proteins.
Further studies are needed to dissect the process of LIMK1mediated regulation of mitosis.
A direct role of LIMK1 in promoting cellular invasion, a
hallmark of metastasis, is also evident from our studies on
Matrigel-based invasion assay. A partial inhibition of LIMK1
reduced the percentage of invading cells to a level comparable
with the BPH-1 cells. However, the effect of ectopic expression
of LIMK1 in BPH-1 cells on promotion of invasion was more
pronounced and significantly higher than the highly metastatic
PC3 cells, suggesting a possible role LIMK1 in the acquisition
of metastatic behavior of prostate tumors. Accordingly, we have
noted a significantly increased expression of LIMK1 in metastatic prostate tumors (data not shown), indicating an association of LIMK1 expression with advanced prostate cancer. A
possible involvement of the Rac, an upstream effector of
LIMK1, in NGF- and EGF-induced increased invasion of prostate cancer has been proposed (24). It is possible that the effect
of growth factors on the increased invasion is mediated through
LIMK1 in advanced prostate cancer in which specific receptors
for NGF and EGF are overexpressed (21, 22). However, it is
unclear how the ectopic expression of LIMK1 promotes cellular
invasion in BPH-1 cells, in which the upstream effectors of
LIMK1 may not be activated in the absence of specific extracellular signals.
Consistent with the effect of LIMK1 in promotion of cellular
invasiveness, a visible alteration in the cell shape and adhesion
pattern was caused by a partial reduction in LIMK1 in prostate
epithelial cells. PC3ASL cells showed discrete stress fibers, and
a more flattened appearance that was typically observed after
Rho activation (17). Interestingly, the effect of LIMK1 in facilitating cell invasion is not mediated through the inactivating
phosphorylation of cofilin. This observation suggests a presently unknown area of possible interactions between LIMK1
and other proteins that are involved in maintenance of cell
behavior such as invasion and locomotion. The presence of two
LIM domains and a PDZ domain at the amino-terminal end of
LIMK1 (1, 37) suggests its possible interaction with other proteins. It is speculated that the effect of LIMK1 is accomplished
through protein-protein interaction, a phenomenon that is sensitive to the stoichiometric balance and can be altered with a
partial reduction in LIMK1 concentration. The putative role of
LIMK1 as the regulator of both G2/M checkpoint and the invasive property of prostate cancer cells and a chromosomal gain
on 7q11.2, the region of localization of LIMK1 gene, in metastatic prostate cancer suggest the possibility of LIMK1 as a
cellular oncogene. Our study on identification of LIMK1 as a
potential promoter of prostate cancer progression should facilitate further characterization of interacting partners involved
in progression of primary tumors and metastasis of advanced
tumors and might provide a novel therapeutic target for prevention of prostate cancer metastasis.
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